45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)

作者：Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan Muppidi, Max J. Gordon, Yandan Yang, Weihong Xu, Theresa Davies‐Hill, Dawei Huang, C. Thomas, Michele Ceribelli, Frances A. Tosto, Anna Marie Juanitez, Amynah Pradhan, C. Morrison, Atekelt Tadese, Colleen Ramsower, Lisa M. Rimsza, Allison P. Jacob, H. Simmons, Elaine S. Jaffe, Mark Roschewski, L. M. Staudt, W. H. Wilson · 发表于：Hematological Oncology · 年份：2025 · DOI：10.1002/hon.70093_45 · 被引用次数：2 · 研究领域：Lymphoma Diagnosis and Treatment

Introduction: MCL is incurable with immunochemotherapy. Oral targeted agents are active but often do not induce durable remissions. We developed multi-agent targeted ViPOR and demonstrated safety and efficacy in MCL (Melani et al. Blood. 2024). Here, we present new and updated efficacy and MRD data for the MCL cohort of our ongoing ViPOR study. Methods: Treatment-naïve (TN) and relapsed/refractory (R/R) MCL pts with adequate organ function were eligible. Venetoclax 400 mg was given PO D2-14 on C2-6 with an initial 12d ramp-up on C2 with fixed-dose ibrutinib 560 mg PO D1-14, prednisone 100 mg PO D1-7, obinutuzumab 1000 mg IV D1-2, and lenalidomide 15 mg PO D1-14 on C1-6 as previously described (Melani et al. Blood. 2024). ViPOR q21d × 6C was given without maintenance. TLS ppx was given to all pts and G-CSF in R/R pts. Baseline CT, PET, BM, and tumor bx was performed with CT after C1, 2, 4, and 6 and PET after C6. CT was then performed q3m × 1y, q4m × 1y, q6m × 1y, and q12m × 2y. MRD was assessed in ctDNA from paired plasma and PBMC samples using clonoSEQ at baseline, during tx, and in f/u. Results: 39 MCL pts (19 R/R & 20 TN) enrolled. Median (range) age was 67y (41–82) with 69% male. Blastoid morphology, Ki-67 > 30%, and TP53 aberration seen in 28%, 37%, and 33%, respectively. High-risk MIPI and MCL35 proliferation score seen in 31% and 20%, respectively. Median (range) prior tx in R/R was 3 (1–7) with prior BTKi in 42% and 63% refractory to last tx. Heme AEs included G3-4 (%...